Trillium and Genentech Enter Into Global License Agreement.

PR Newswire Europe, December, 2004

TORONTO, December 14 /PRNewswire/ -- Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, announced today that it has entered into an agreement with Genentech, Inc. (NYSE: DNA), granting the latter exclusive worldwide rights to TTI's technology to develop and commercialise products directed against a particular target (undisclosed).

Under the terms of the agreement, TTI will receive an upfront payment, research funding and milestone payments. TTI will also receive royalties on product sales in the event of commercialised products. No other financial terms were disclosed. The companies will together complete preclinical development activities, while Genentech will be solely responsible for clinical development, regulatory approvals,...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here